{"bill": {"#text": " \n", "form": {"current-chamber": {"#tail": " \n", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n", "congress": {"#tail": "\n", "#text": "113th CONGRESS"}, "#tail": " \n", "legis-num": {"#tail": " \n", "#text": "H. R. 5750"}, "official-title": {"#tail": " \n", "#text": "To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes."}, "session": {"#tail": "\n", "#text": "2d Session"}, "distribution-code": {"#tail": " \n", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": " \n", "@date": "20141120", "#text": "November 20, 2014"}, "#tail": " \n", "action-desc": {"#tail": "\n", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Bilirakis", "@name-id": "B001257"}, "cosponsor": [{"#tail": ", ", "#text": "Mr. Butterfield", "@name-id": "B001251"}, {"#tail": ", and ", "#text": "Mr. McCaul", "@name-id": "M001157"}, {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Hastings of Florida", "@name-id": "H000324"}]}, "#text": " \n"}, "legis-type": {"#tail": " \n", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "HC5DECB181634406C9C48D63A237C62F2", "@public-private": "public", "legis-body": {"#tail": " \n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": " \n", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014", "@value": "Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H1634C085364249C5A2256EA3F1330AA5"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": " \n", "#text": "Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition"}, "subsection": [{"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by inserting after ", "@entity-type": "act", "#text": "Chapter V of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:V"}, "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505E of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355f", "@value": "usc/21/355f"}, "@parsable-cite": "usc/21/355f", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "section": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "505F."}, "header": {"#tail": " \n", "#text": "Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition"}, "subsection": [{"#tail": " \n", "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": " \n", "#text": "Designation"}, "paragraph": [{"#tail": " \n", "@id": "H945DC4A2834940BFA08F536BBA2DD8A1", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general"}, "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall designate a drug as a drug approved for a new indication to prevent, diagnose, or treat a rare disease or condition for purposes of granting the extensions under subsection (b) if\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "#text": "\n                ", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": ", but was not so approved or licensed for the new indication;", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}], "#text": "prior to approval of an application or supplemental application for the new indication, the drug was approved or licensed for marketing under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "#text": "\n                  ", "@id": "HCF3D73FE3E0843E7AF1578289AFFEE2D", "@commented": "no"}, {"#tail": " \n", "clause": [{"#tail": " \n", "text": {"#tail": "\n                  ", "#text": "the sponsor of the approved or licensed drug files an application or a supplemental application for approval of the new indication for use of the drug to prevent, diagnose, or treat the rare disease or condition; and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "yes-display-inline", "#text": "\n                    ", "@id": "H21B90314A58446199F637E392E981E38", "@commented": "no"}, {"@indent": "up1", "#tail": "\n                ", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " approves the application or supplemental application; and", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the "}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "#text": "\n                    ", "@id": "H4753554963CE42E98B8F14CFC23086DD", "@commented": "no"}], "enum": {"#tail": " \n", "#text": "(B)"}, "@id": "H4D1E60FB389E4EED83FA4636171890A5", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " under paragraph (4) respecting the designation of the drug.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the application or supplemental application for the new indication contains the consent of the applicant to notice being given by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "HF778FDCF96834108B0F1E8361D87064E", "#text": "\n                  "}]}, {"#tail": " \n", "@id": "HA1545F50310D491F885843367D930944", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Revocation of designation"}, "text": {"#tail": " \n", "@display-inline": "yes-display-inline"}, "#text": "\n                ", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n                ", "#text": "Except as provided in subparagraph (B), a designation under this subsection shall not be revoked for any reason."}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In general"}, "#text": "\n                  ", "@id": "H619F6CBDC404440CBFA303CFA7BF687B"}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may revoke a designation of a drug under paragraph (1) if the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " finds that the application or supplemental application resulting in such designation contained an untrue statement of material fact.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Exception"}, "#text": "\n                  ", "@id": "H86B745C6360C44F0A1A6A44F3C62C0B8"}]}, {"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " of any discontinuance of the production of the drug for solely commercial reasons at least one year before such discontinuance.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "A designation of a drug under paragraph (1) shall be subject to the condition that the sponsor of the drug will notify the "}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Notification prior to discontinuance of production for solely commercial reasons"}, "#text": "\n                ", "@id": "HBDF2609577294A9988CE92C211C8779D"}, {"#tail": " ", "text": {"#tail": "\n              ", "#text": "Notice respecting the designation of a drug under paragraph (1) shall be made available to the public."}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Notice to public"}, "#text": "\n                ", "@id": "H68F31FD47F614CA18808D9A05B7E8E86"}], "#text": "\n              ", "@id": "H9B57939C43DF41ED9E5C2710676A81D6"}, {"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " designates a drug as a drug approved for a new indication for a rare disease or condition, as described in subsection (a)(1)\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "If the "}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Extension"}, "paragraph": [{"#tail": " \n", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "subsections (c)(3)(E)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:ii"}, {"#tail": ", the 3-year periods described in ", "@entity-type": "act", "#text": "(j)(5)(F)(ii) of section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:ii"}, {"#tail": " and ", "@entity-type": "act", "#text": "clauses (iii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:iii"}, {"#tail": " and ", "@entity-type": "act", "#text": "(iv) of subsection (c)(3)(E)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:iv"}, {"#tail": " and ", "@entity-type": "act", "#text": "clauses (iii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:iii"}, {"#tail": ", and the 7-year period described in ", "@entity-type": "act", "#text": "(iv) of subsection (j)(5)(F) of section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:iv"}, {"#tail": ", as applicable, shall be extended by 6 months; or", "@entity-type": "act", "#text": "section 527", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}], "#text": "the 4-, 5-, and seven and one-half year periods described in "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n                  ", "@id": "H790789A58B3A4632A2B5E25499F2BF1E"}, {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "subparagraphs (A)", "@value": "Public Health Service Act/s:351/ss:k/p:7/sp:A"}, {"#tail": " and the 7-year period described in ", "@entity-type": "act", "#text": "(B) of section 351(k)(7) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:k/p:7/sp:B"}, {"#tail": ", as applicable, shall be extended by 6 months; and", "@entity-type": "act", "#text": "section 527", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}], "#text": "the 4- and 12-year periods described in "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "#text": "\n                  ", "@id": "HDDC56CE0B099413DB5BB8CAB8E783403"}], "enum": {"#tail": " \n", "#text": "(1)"}, "@id": "H921BF8C471FE458A859B00119588AE5D", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": " \n", "#text": "if, at the time a drug is designated under subsection (a)(1)\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "#text": "\n                ", "@id": "H5AAACEBC7F7B4CBCA1176B40967A768E", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (b)(2)(A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:ii"}, {"#tail": " or a listed patent for which a certification has been submitted under ", "@entity-type": "act", "#text": "(j)(2)(A)(vii)(II) of section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:II"}, {"#tail": " or ", "@entity-type": "act", "#text": "subsections (b)(2)(A)(iii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:iii"}, {"#tail": ", the period during which an application may not be approved under ", "@entity-type": "act", "#text": "(j)(2)(A)(vii)(III) of section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:III"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(c)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3"}, {"#tail": " shall be extended by a period of 6 months after the date the patent expires (including any patent extensions); or", "@entity-type": "act", "#text": "section 505(j)(5)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B"}], "#text": "the drug is the subject of a listed patent for which a certification has been submitted under "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "HA397FEBEBA6A40A7BB9D8071F9780CBB", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (b)(2)(A)(iv)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:iv"}, {"#tail": ", and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed, the period during which an application may not be approved under ", "@entity-type": "act", "#text": "(j)(2)(A)(vii)(IV) of section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(c)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3"}, {"#tail": " shall be extended by a period of 6 months after the date the patent expires (including any patent extensions).", "@entity-type": "act", "#text": "section 505(j)(5)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B"}], "#text": "the drug is the subject of a listed patent for which a certification has been submitted under "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H3ECFD1B23FE84F2BBC55D47F025043DB", "#text": "\n                  "}]}], "#text": "\n              ", "@id": "H98F8A413C9FC45E9BB81B0C75EF0B59E"}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "sections 505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": " and ", "@entity-type": "act", "#text": "505E of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E"}, {"#tail": ", as applicable, with respect to the drug. ", "@entity-type": "act", "#text": "section 351(m) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:m"}], "#text": "Any extension under subsection (b) of a period shall be in addition to any extension of the periods under "}, "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n              ", "#text": "Relation to pediatric and qualified infectious disease product exclusivity"}, "#text": "\n              ", "@id": "H3BCCF85E90FD43DBB5AD6735A4B823EA"}, {"#tail": " \n", "text": {"#tail": "\n            ", "#text": "The extension described in subsection (b) shall not apply if the drug designated under subsection (a)(1) has previously received an extension by operation of subsection (b)."}, "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n              ", "#text": "Limitations"}, "#text": "\n              ", "@id": "H83964ED1013C4342A9C11156FB1106DD"}, {"#tail": " \n", "enum": {"#tail": "\n              ", "#text": "(e)"}, "header": {"#tail": " \n", "#text": "Regulations"}, "paragraph": [{"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall adopt final regulations implementing this section.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Not later than 2 years after the date of enactment of this section, the "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general"}, "#text": "\n                ", "@id": "HAAB5D3DDD1964111A0F17E88EDED11E1"}, {"#tail": " \n", "@id": "HC9F5B83071134D17BE39106FDE3B35B6", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Procedure"}, "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "In promulgating a regulation implementing this section, the "}, "#text": "\n                ", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n                ", "#text": "issue a notice of proposed rulemaking that includes the proposed regulation;"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "HA0881D1627B74B78AE110312F901898D", "#text": "\n                  "}, {"#tail": " \n", "text": {"#tail": "\n                ", "#text": "provide a period of not less than 60 days for comments on the proposed regulation; and"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "HC46F4F1390E54C168E4D206B37976249", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "publish the final regulation not less than 30 days before the effective date of the regulation."}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "HB91300A1B0174D668B0A89CAB12988D2", "#text": "\n                  "}]}, {"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall promulgate regulations implementing this section only as described in paragraph (2), except that the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may issue interim guidance for sponsors seeking to submit an application or supplemental application described in subsection (a) prior to the promulgation of such regulations.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Notwithstanding any other provision of law, the "}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Restrictions"}, "#text": "\n                ", "@id": "H9CDEAE31307D4E1A87F9244258ADFF25"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall designate drugs under subsection (a) prior to the promulgation of regulations under this subsection, if such drugs meet the criteria described in subsection (a).", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Designation prior to regulations"}, "#text": "\n                ", "@id": "HC61FABAB76634C358A5C460254A88E81"}], "#text": "\n              ", "@id": "H25088E2AA095476683B7EA9055F1A1EB"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 526(a)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:526/ss:a/p:2"}, "term": {"#tail": " has the meaning given to such term in ", "#text": "rare disease or condition"}, "#text": "In this section, the term "}, "enum": {"#tail": "\n              ", "#text": "(f)"}, "header": {"#tail": "\n              ", "#text": "Definition"}, "#text": "\n              ", "@id": "HA4680B40439F497781894034DA594E8B"}], "#text": "\n            ", "@id": "H560BFCBA10564A548BA8392BD950EDD9"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "H96006B1DCB094C3CAD77F5C07B645676"}, "#text": "\n        ", "@id": "HD74E8C4517854C30AB86855F2AC5BD6A"}, {"#tail": " \n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", as added by subsection (a), applies only with respect to a drug for which an application or supplemental application described in ", "@entity-type": "act", "#text": "Section 505F of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505F", "@proposed": "true"}, {"#tail": " is first approved under ", "@entity-type": "act", "#text": "subsection (a)(1)(B)(i) of such section 505F", "@value": "Federal Food, Drug, and Cosmetic Act/s:505F/ss:a/p:1/sp:B/cl:i", "@proposed": "true"}], "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(c) of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(c)", "@value": "usc/21/355/c"}, "@parsable-cite": "usc/21/355", "#text": "\n            ", "@legal-doc": "usc"}}, {"#tail": " on or after the date of the enactment of this Act.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(a)", "@value": "usc/42/262/a"}, "@parsable-cite": "usc/42/262", "#text": "\n            ", "@legal-doc": "usc"}}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Application"}, "#text": "\n        ", "@id": "HDD3A4A4DA95B434CAF3E66DAD472EFF1"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": " \n", "#text": "Conforming amendments"}, "paragraph": [{"#tail": " \n", "@id": "H2B5630C5078044A1BE6AC401F824281F", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Relation to pediatric exclusivity for drugs"}, "text": {"#tail": " \n", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 505A of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355a", "@value": "usc/21/355a"}, "@parsable-cite": "usc/21/355a", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "#text": "\n          ", "subparagraph": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "in subsection (b), by adding at the end the following:"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "paragraph": {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505F", "@value": "Federal Food, Drug, and Cosmetic Act/s:505F", "@proposed": "true"}, "#text": "Notwithstanding the references in subsection (b)(1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in subsection (b)(1) shall be in addition to any extensions under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Relation to exclusivity for a drug approved for a new indication for a rare disease or condition"}, "#text": "\n                ", "@id": "H8ED66959EB964C30A49028498944A95C"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "HC0CBAF70C66A4DAFA0110F93F80BE1C2"}, "#text": "\n            ", "@id": "H7C3556D77C2A4EB9A74B7E0DAE88E5CA"}, {"#tail": "\n        ", "text": {"#tail": " \n", "#text": "in subsection (c), by adding at the end the following:"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "."}, "#tail": "\n          ", "paragraph": {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505F", "@value": "Federal Food, Drug, and Cosmetic Act/s:505F", "@proposed": "true"}, "#text": "Notwithstanding the references in subsection (c)(1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in subsection (c)(1) shall be in addition to any extensions under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Relation to exclusivity for a drug approved for a new indication for a rare disease or condition"}, "#text": "\n                ", "@id": "HCDC184EAA3D74432AE074DA4ECB4B07B"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "H57C3892EA8224C568E68D41A7899BB57"}, "#text": "\n            ", "@id": "HFEC7D42427C04B8E973F073290984731"}]}, {"#tail": " \n", "@id": "HB208CD99961E4DAAB736E762EF5A24A7", "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Relation to exclusivity for new qualified infectious disease products that are drugs"}, "text": {"#tail": " \n", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Subsection (b) of section 505E of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E/ss:b"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355f", "@value": "usc/21/355f"}, "@parsable-cite": "usc/21/355f", "#text": "\n              ", "@legal-doc": "usc"}}}, "#text": "\n          ", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "quote": {"#tail": "; and", "header-in-text": {"#tail": "\n              ", "@style": "OLC", "#text": "Relation to pediatric exclusivity and exclusivity for a drug approved for a new indication for a rare disease or condition", "@level": "subsection"}, "#text": "\n                "}, "#text": "by amending the subsection heading to read as follows: "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H5879ED8E2BAD40D2BF144C1A731C5038", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "quote": [{"#tail": " and inserting ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "section 505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, "#text": "any extension of the period under "}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "sections 505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": "\n              ", "@entity-type": "act", "#text": "505F", "@value": "Federal Food, Drug, and Cosmetic Act/s:505F", "@proposed": "true"}], "#text": "any extension of the periods under "}], "#text": "by striking "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "H0E02A45D70C04FD7B0835795717D17AE", "#text": "\n            "}]}, {"#tail": " ", "text": {"#tail": " \n", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 351(m) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:m"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(m)", "@value": "usc/42/262/m"}, "@parsable-cite": "usc/42/262", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "header": {"#tail": "\n          ", "#text": "Relation to pediatric exclusivity for biological products"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "paragraph": {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505F", "@value": "Federal Food, Drug, and Cosmetic Act/s:505F", "@proposed": "true"}, "#text": "Notwithstanding the references in paragraphs (2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in such paragraphs shall be in addition to any extensions under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "header": {"#tail": "\n              ", "#text": "Relation to exclusivity for a biological product approved for a new indication for a rare disease or condition"}, "#text": "\n              ", "@id": "HA68E8ED74E9044F58FB25B26C650FD94"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "HA700D9BE31E4491AAE384189187F2AF3"}, "#text": "\n          ", "@id": "HDD6A59EB5B864503A0CC521B5412D096"}], "#text": "\n        ", "@id": "H3AFCFE6B47AA446FB8F6CB658D0E69BA"}], "#text": "\n      ", "@id": "H3BE316C9233F40C08138A1C18D07B72C"}], "#text": " \n", "@id": "HFAF6C76D51664237AA6D35EC8E4A6C1B"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-11-20"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 5750 IH: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}